Wednesday, 18 Oct 2017

You are here

Adalimumab Effective in Pediatric Plaque Psoriasis

Adalimumab is currently FDA approved for use in adult psoriasis, pediatric Crohn's disease and polyarticular juvenile idiopathic arthritis.  The current Lancet trial assesses the efficacy and safety of adalimumab in children and adolescents with severe plaque psoriasis.

This multicenter, multinational study enrolled 114 children ages 4 to 18 yrs with severe plaque psoriasis and randomized them to treatment with adalimumab (ADA) (0·8 mg/kg or 0·4 mg/kg subcutaneously)every other week after week 1, or oral methotrexate (MTX) once weekly (0·1–0·4 mg/kg) for 16 weeks.

A week 16  PASI75 was achieved moreso with ADA (58%) compared to MTX (32%).

Clearing or minimal psoriasis was seen with 61% of ADA and 41% of the MTX patients.

There were no unexpected toxicities or infections and 3 serious adverse events were reported, all in patients in the adalimumab 0·4 mg/kg group, and were not judged to be related to study drug.

ADA appears to be effective and safe in children with plaque psoriasis. 

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Stelara FDA Approved for Use in Adolescent Psoriasis

Johnson & Johnson has announced that they have received an expanded FDA approval for the use of ustekinumab (Stelara) in treating adolescent patients, aged 12 and over, with moderate to severe plaque psoriais.

Spinal X-ray Inhibition in Ankylosing Spondylitis Best Achieved by Control of Activity

Although tumour necrosis factor inhibitors (TNFi) are highly effective (on clinical grounds) in ankylosing spondylitis (AS), proof that they may alter the course of spinal radiographic progression has been scant. That's primarily because of the insidisous nature of the disease, comparatively slow progression and difficulties in imaging and scoring the sacroiliac and axial joints. 

Alcohol Related Deaths Increased in Psoriasis

JAMA Dermatology has published a report showing psoriasis carries a 60% greater risk alcohol-related death compared with those without psoriasis. (Citation source:

Psoriasis Increases Risk of Major Adverse Cardiovascular Events

A report in the Journal of the American Academy of Dermatology shows that psoriasis duration and inflammation may result in cardiovascular inflammation and an increased risk of major adverse CV events.

Psoriasis Doubles Mortality Risk

Noe and colleagues have reported in the Journal of Investigative Dermatology that by estimating the extent of skin involvement in psoriasis (%BSA) they may assess future mortality risk. 

Psoriasis patients with 10% or more body surface area (BSA) involvement nearly doubled their risk of early death than those without the disease.